| Hepatobiliary Neoplasm altered in cohorts of …ALTERED_INderived200 of 326show all (up to 200) |
|---|
| ← altered in cohorts of | HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf158 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMTA1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZB 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDOST 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | E2F2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM43B 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO42 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMGCL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPR 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HP1BP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPG2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR1D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF21 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDM1A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACTBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LDLRAD2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC38 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LUZP1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10-NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPHP4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAX7 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDIK1L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDPN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PINK1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PITHD1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2C 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2E 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2F 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF12 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF14 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF18 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF20 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF25 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF26 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF27 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF33 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF9 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1GAP 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCC2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF186 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPEN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEX46 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBR4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP48 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS13D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF436 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASH1L 279 / 377 cases (74 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUSC1 277 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA3 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM189B 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PKLR 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC50A1 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THBS3 276 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM15 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLK2 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST2 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA1 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FDPS 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INSRR 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTX1 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SCAMP3 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM46 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZBTB7B 275 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DCST1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DPM3 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EFNA4 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GBA 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HCN3 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KHDC4 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KRTCAP2 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LENEP 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUC1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | YY1AP1 274 / 377 cases (73 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CKS1B 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DAP3 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLAD1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLG 273 / 377 cases (72 %) · ssm · TCGA-LIHC · largest of 4 cohorts | — | — | Hepatocellular Carcinoma | 4 | Observed | gdc | graph → |
| ← altered in cohorts of | GON4L 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MSTO1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PBXIP1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PYGO2 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RIT1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RXFP4 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHC1 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC27A3 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMG5 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYT11 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNN 273 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IQGAP3 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMNA 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MEX3A 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMVK 272 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCAN 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BMP1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCT3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHRNB2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRTC2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND4B 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCRL5 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GATAD2B 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ISG20L2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNN3 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC71 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MNDA 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NES 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPR1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTRK1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIWIL2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMF1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POLR3D 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAB25 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SEMA4A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D2A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SSR2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STYXL2 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM79 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFRSF10A 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBAP2L 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBE2Q1 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBQLN4 271 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADAM28 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP30 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATF6 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP8B2 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CRABP2 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CREB3L4 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ETV3 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FCGR3B 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMP 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HAPLN2 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HDGF 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NIT1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OR6Y1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAQR6 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PEAR1 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | REEP4 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNAPIN 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP21 270 / 377 cases (72 %) · ssm · TCGA-LIHC | — | — | Hepatocellular Carcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTN 177 / 494 cases (36 %) · ssm · hcc_clca_2024 · largest of 8 cohorts | — | — | Hepatocellular Carcinoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 466 / 1,370 cases (34 %) · ssm · hcc_msk_2024 · largest of 18 cohorts | — | — | Hepatocellular Carcinoma | 18 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 105 / 494 cases (21 %) · ssm · hcc_clca_2024 · largest of 8 cohorts | — | — | Hepatocellular Carcinoma | 8 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID1A 226 / 1,370 cases (16 %) · ssm · hcc_msk_2024 · largest of 15 cohorts | — | — | Hepatocellular Carcinoma | 15 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TERT 225 / 1,370 cases (16 %) · ssm · hcc_msk_2024 · largest of 5 cohorts | — | — | Hepatocellular Carcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ALB 73 / 494 cases (15 %) · ssm · hcc_clca_2024 · largest of 5 cohorts | — | — | Hepatocellular Carcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCLO 67 / 494 cases (14 %) · ssm · hcc_clca_2024 · largest of 8 cohorts | — | — | Hepatocellular Carcinoma | 8 | Observed | cbioportal | graph → |